British Journal of Cancer - McMaster Experts

publication venue for

Timeliness of diagnosis and treatment: the challenge of childhood cancers. 125:1612-1620. 2021
Correction to: Timeliness of diagnosis and treatment: the challenge of childhood cancers. 125:1178-1178. 2021
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative. 124:1503-1512. 2021
The association between colorectal cancer and prior antibiotic prescriptions: case control study. 122:912-917. 2020
International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. 121:15-21. 2019
Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. 119:707-712. 2018
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). 118:1434-1441. 2018
Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. 118:1238-1242. 2018
The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation. 118:1399-1405. 2018
A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features. 119:508-516. 2018
Evaluation of treatment-related mortality among paediatric cancer deaths: a population based analysis. 116:540-545. 2017
Impact of cause of death adjudication on the results of the European prostate cancer screening trial. 116:141-148. 2017
The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. 114:1160-1164. 2016
Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients. 114:616-622. 2016
Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis. 114:631-637. 2016
TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial. 113:722-728. 2015
18F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer. 112:1737-1743. 2015
The impact of age on changes in quality of life among breast cancer survivors treated with breast-conserving surgery and radiotherapy. 112:636-643. 2015
A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177. 111:2262-2267. 2014
Refinement of the Symptom Screening in Pediatrics Tool (SSPedi). 111:1262-1268. 2014
Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis. 110:2593-2603. 2014
Validation of the Children’s International Mucositis Evaluation Scale (ChIMES) in paediatric cancer and SCT. 109:2515-2522. 2013
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). 109:943-949. 2013
Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. 108:2021-2032. 2013
Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo. 108:327-333. 2013
Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials. 106:1626-1637. 2012
Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. 105:1469-1473. 2011
Postmenopausal circulating levels of 2- and 16α-hydroxyestrone and risk of endometrial cancer. 105:1458-1464. 2011
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. 105:709-722. 2011
Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. 105:44-52. 2011
Statistical issues in the use of dynamic allocation methods for balancing baseline covariates. 104:1711-1715. 2011
Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. 104:1377-1383. 2011
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. 104:756-762. 2011
Family history and the risk of gastric cancer. 102:237-242. 2010
Incidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador. 100:1026-1031. 2009
Identification of paediatric cancer patients with poor quality of life. 100:82-88. 2009
The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. 97:302-307. 2007
Bisphosphonates: are they standard of care for the treatment of breast cancer?. 96:1781-1782. 2007
Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer. 96:1526-1531. 2007
Have we been guilty of ageism in the primary treatment of breast cancer?. 96:1011-1012. 2007
Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. 94:1452-1459. 2006
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. 94:1136-1143. 2006
Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. 94:1011-1015. 2006
Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid. 92:298-304. 2005
Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. 91:1301-1307. 2004
Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. 90:1429-1436. 2004
Relationship between clonogenic radiosensitivity, radiation-induced apoptosis and DNA damage/repair in human colon cancer cells. 89:2277-2283. 2003
Monoamine oxidase inhibitors l-deprenyl and clorgyline protect nonmalignant human cells from ionising radiation and chemotherapy toxicity. 89:1979-1986. 2003
Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition. 89:954-954. 2003
Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer. 89:1031-1034. 2003
European cooperation for clinical practice guidelines in cancer. 89:S1-S3. 2003
Oestradiol enhances tumour regression induced by B7-1/IL-2 adenoviral gene transfer in a murine model of breast cancer. 89:385-390. 2003
A proliferation-dependent bystander effect in primary porcine and human urothelial explants in response to targeted irradiation. 88:767-774. 2003
Particulate debris from a titanium metal prosthesis induces genomic instability in primary human fibroblast cells. 88:548-552. 2003
Alcohol, tobacco and breast cancer – collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease. 87:1234-1245. 2002
Risk factors for oesophageal, lung, oral and laryngeal cancers in black South Africans. 86:1751-1756. 2002
A controlled ‘before-after’ study: impact of a clinical guidelines programme and regional cancer network organization on medical practice. 86:313-321. 2002
‘Background to clinical guidelines in cancer’: SOR, a programmatic approach to guideline development and aftercare. 84:1-3. 2001
Production of a signal by irradiated cells which leads to a response in unirradiated cells characteristic of initiation of apoptosis. 83:1223-1230. 2000
True. 82:1740-1746. 2000
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. 82:1427-1432. 2000
Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions. 82:361-367. 2000
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. 81:490-495. 1999
Wt-p53 action in human leukaemia cell lines corresponding to different stages of differentiation. 77:1429-1438. 1998
The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. 75:1534-1542. 1997
A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice. 75:1014-1020. 1997
Erratum: The sensitivity of normal brain and intracranially implanted VX2 tumour to interstitial photodynamic therapy. 74:1691-1691. 1996
p53 protein is absent from the serum of patients with lung cancer. 74:1434-1440. 1996
Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. 74:1242-1247. 1996
A randomised trial of two information packages distributed to new cancer patients before their initial appointment at a regional cancer centre. 73:1588-1593. 1996
The sensitivity of normal brain and intracranially implanted VX2 tumour to interstitial photodynamic therapy. 73:332-343. 1996
Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. 72:720-727. 1995
Prostate-specific antigen in serum of women with breast cancer. 72:728-731. 1995
Expression of p53 in urothelial cell cultures from tumour-bearing and tumour-free patients. 71:25-29. 1995
The comprehensive assessment of health status in survivors of childhood cancer: application to high-risk acute lymphoblastic leukaemia. 67:1047-1052. 1993
A comparison of membrane properties and composition between cell lines selected and transfected for multi-drug resistance. 66:781-786. 1992
The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. 65:737-743. 1992
The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation. 65:130-132. 1992
Reversal of intrinsic multidrug resistance in Chinese hamster ovary cells by amiloride analogs. 63:247-251. 1991
Endocrine disorders following treatment of childhood brain tumours. 61:622-625. 1990
Investigation of the relationship between altered intracellular pH and multidrug resistance in mammalian cells. 61:568-572. 1990
Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy?. 59:910-914. 1989
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. 58:779-782. 1988
Cross resistance pattern towards anticancer drugs of a human carcinoma multidrug-resistant cell line. 58:441-447. 1988
Human ovarian carcinoma: evidence for patient-related differences in susceptibility to cytotoxic effectors that attack different cellular subpopulations within a tumour. 58:415-418. 1988
Double antibody radioimmunoassay for monitoring metastatic breast cancer. 58:362-367. 1988
A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. 57:94-99. 1988
Cellular heterogeneity in normal and neoplastic human urothelium: A study using murine monoclonal antibodies. 56:439-444. 1987
DNA quaternary structure in the radiation sensitivity of human lymphocytes--a proposed role of copper.. 8:141-144. 1987
RADIATION TRANSFORMATION IN DIFFERENTIATED HUMAN-CELLS IN CULTURE. 53:251-252. 1986
Evaluation of screening programmes for gynaecological cancer. 52:669-673. 1985
Soft-tissue injury caused by antineoplastic drugs is inhibited by topical dimethyl sulphoxide and alpha tocopherol. 48:873-876. 1983
Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents: A study of active intervention. 44:267-269. 1981
Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy. 32:323-330. 1975
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas 2006
Hypoxia inducible factor (HIF)-1 alpha in non-small cell lung cancer (NSCLC) 2002
beta-catenin in non-small cell lung cancer (NSCLC) 2002
Effects of low level radiation in normal urothelial cells 1999
Prognostic significance of platelet microvessel counts in non-small cell lung cancer 1999
CHANGES IN PROTEIN EXPRESSION DURING MELANOMA DIFFERENTIATION DETERMINED BY COMPUTER-ANALYSIS OF 2-D GELS 1990
CISPLATIN INVOKED LEAD MOBILIZATION STUDIES 1990
DEVELOPMENT OF A TECHNIQUE FOR OPTIMIZING CANCER-THERAPY USING A HUMAN EPITHELIAL MODEL SYSTEM 1988
LETHAL MUTATIONS AND THEIR EFFECT ON THE APPLICATION OF RADIOBIOLOGICAL RESULTS TO RADIOTHERAPY 1988
ENDOCRINE DISORDERS FOLLOWING TREATMENT OF BRAIN-TUMORS IN CHILDHOOD 1987
GROWTH FAILURE FOLLOWING IRRADIATION IN CHILDREN WITH BRAIN-TUMORS 1987
A HISTOPATHOLOGICAL AND DNA CYTOPHOTOMETRIC STUDY OF BENIGN AND MALIGNANT ESOPHAGEAL TISSUE CULTURED INVITRO 1987
A MODEL FOR THE STUDY OF TREATMENT RESPONSE IN HUMAN NORMAL AND TUMOR-CELLS INVITRO 1987
ANALYSIS OF THE HUMAN ANTI-MOUSE IG RESPONSE IN PATIENTS RECEIVING MURINE MONOCLONAL-ANTIBODIES 1986
LACK OF CORRELATION BETWEEN EXCISION REPAIR OF UV DAMAGE AND ADENOVIRUS REACTIVATION IN AN XP(D)-LIKE CELL-LINE 1986
RADIATION RESPONSE OF HUMAN ESOPHAGEAL CELLS-INVITRO 1986
HUMAN ANTI-MOUSE IMMUNOGLOBULIN RESPONSES IN PATIENTS RECEIVING MONOCLONAL-ANTIBODIES 1985
THE EFFECT OF ALTERED ENERGY-METABOLISM ON THE PRIMARY AND SECONDARY SURVIVAL-CURVE SHOULDER OF IRRADIATED CHO-KI CELLS 1984

British Journal of Cancer Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)